HWHongyu Wu

Hongyu Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hongyu Wu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Chaojing Zheng

    The Key Laboratory of Zhejiang Province for Aptamers and Theranostics Zhejiang Cancer Hospital Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou Zhejiang P. R. China

    1 shared publication
  • Chaoxia Zou

    Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin 150081, China; Translational Medicine Research and Cooperation Center of Northern China, Heilongjiang Academy of Medicine Sciences, Harbin 150081, China

    1 shared publication
  • Chenkai Zhang

    Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China

    1 shared publication
  • Chunlin Wang

    Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China

    1 shared publication
  • Guiyu Wang

    Department of Colorectal Tumor Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication
  • Hanqing Hu

    Department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Aptamer‐Targeted PrPC Drives Colorectal Cancer Metastasis via a LYN‐STAT3 Complex and Enables Liquid Biopsy Detection

    by Chunlin Wang, Hongyu Wu, Chaojing Zheng, Hao Zhang, Xiaoqiu Wu, Jiaqi Wang, Zewen Chang, Jun Xiang, Yunxiao Liu, Chenkai Zhang, et al.

    Colorectal cancer (CRC) poses a significant global health challenge, highlighting the need for better diagnostic tools and molecular targets. Compared to traditional antibodies, aptamers, which are single‐stranded oligonucleotides with high affinity and low immunogenicity, offer an ideal platform for discovering novel biomarkers. Based on this approach, we used the Cell‐SELEX strategy to develop a high‐affinity aptamer‐based probe, WHY‐3E, which successfully identified the cellular prion protein (PrPC) as a key molecular target. We observed that PrPC was significantly upregulated in CRC tissues, strongly correlating with unfavorable clinical outcomes. Functionally, PrPC promotes malignant phenotypes, including migration and invasion, by regulating MSN. Mechanistically, we revealed that PrPC physically translocates from the cell surface to the cytoplasm via endocytosis. Once internalized, it interacts with the STAT3‐NTD and LYN‐SH domains, facilitating the ternary complex formation that enhances LYN‐mediated STAT3 phosphorylation, ultimately increasing MSN transcriptional activity. Moreover, the deubiquitinase USP18 stabilizes PrPC by removing its Lys48‐linked ubiquitin chains, ensuring the continuous activation of this oncogenic axis. Notably, the WHY‐3E aptamer achieved 90.6% sensitivity and 89.0% specificity in detecting PrPC‐positive circulating exosomes in patient cohorts. These findings deepen the mechanistic understanding of CRC progression and offer novel strategic avenues for PrPC‐targeted aptamer applications in non‐invasive diagnostics.